Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is leading the healthcare industry with their innovative technology, Mpower, and strong portfolio of over 340,000 products. This, coupled with their prime vendor relationships, manufacturing capabilities, and expanding global presence, positions Medline for continued growth. The company's solid financials and commitment to debt reduction and automation make it an attractive investment opportunity; however, competition and industry challenges must be carefully monitored.

Bears say

Medline is facing temporary headwinds in the form of macroeconomic challenges, such as the conflict in the Middle East, which may result in higher inventory costs and potentially lead to price increases for customers. The company's strong volume growth in FY 2025 helped to offset margin pressures caused by tariffs and showcase its growth potential. However, with competition also facing similar challenges, Medline may struggle to gain market share in the future, impacting its economic profit and overall shareholder value.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.